Shopping Cart 0
Cart Subtotal
USD 0

aTyr Pharma Inc (LIFE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. The company's ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to the neuropilin-2 receptor harness immune engagement in interstitial lung diseases and other immune-mediated diseases. It also concentrates on research and development of extracellular functionality of tRNA synthetases. ATyr Pharma also develops drugs for cancer, inflammation, neurodegenerative diseases, and metabolic disorders. The company collaborates with research institutions for its research and development activities. ATyr Pharma is headquartered in San Diego, California, the US.

aTyr Pharma Inc (LIFE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

aTyr Pharma Raises USD76 Million in Series E Financing 11

aTyr Pharma Raises USD 49 Million In Series D Financing 13

Partnerships 14

Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14

aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15

Equity Offering 17

aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 17

aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 18

aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 20

aTyr Pharma Raises USD86.3 Million in IPO of Shares 21

aTyr Pharma Inc-Key Competitors 23

aTyr Pharma Inc-Key Employees 24

aTyr Pharma Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Aug 14, 2018: aTyr Pharma announces second quarter 2018 operating results and provides corporate update 26

May 14, 2018: aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring 28

Mar 19, 2018: aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update 29

Nov 14, 2017: aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update 31

Aug 14, 2017: aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline 33

May 11, 2017: aTyr Pharma Announces First Quarter 2017 Operating Results 35

Mar 16, 2017: aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results 37

Corporate Communications 39

Oct 15, 2018: aTyr Pharma announces leadership transition 39

Jul 31, 2018: aTyr pharma appoints Jill Broadfoot as chief financial officer 40

Nov 01, 2017: aTyr Pharma Announces Leadership Transition 41

Apr 10, 2017: aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors 42

Apr 03, 2017: aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors 43

Product News 44

12/21/2017: aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium 44

09/27/2017: aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society 45

05/15/2017: aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar 46

04/24/2017: aTyr Pharma Announces Promising Top-Line Results from Resolaris Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy 47

04/24/2017: aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting 48

Product Approvals 49

Mar 03, 2017: aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris 49

Feb 28, 2017: aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris 50

Jan 18, 2017: FDA Grants Fast Track Designation for aTyr's Resolaris to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris 51

Clinical Trials 52

Nov 27, 2017: aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923) 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

aTyr Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

aTyr Pharma Raises USD76 Million in Series E Financing 11

aTyr Pharma Raises USD 49 Million In Series D Financing 13

Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14

aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15

aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 17

aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 18

aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 20

aTyr Pharma Raises USD86.3 Million in IPO of Shares 21

aTyr Pharma Inc, Key Competitors 23

aTyr Pharma Inc, Key Employees 24

aTyr Pharma Inc, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

aTyr Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. The company's ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to the neuropilin-2 receptor harness immune engagement in interstitial lung diseases and other immune-mediated diseases. It also concentrates on research and development of extracellular functionality of tRNA synthetases. ATyr Pharma also develops drugs for cancer, inflammation, neurodegenerative diseases, and metabolic disorders. The company collaborates with research institutions for its research and development activities. ATyr Pharma is headquartered in San Diego, California, the US.

aTyr Pharma Inc (LIFE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

aTyr Pharma Raises USD76 Million in Series E Financing 11

aTyr Pharma Raises USD 49 Million In Series D Financing 13

Partnerships 14

Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14

aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15

Equity Offering 17

aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 17

aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 18

aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 20

aTyr Pharma Raises USD86.3 Million in IPO of Shares 21

aTyr Pharma Inc-Key Competitors 23

aTyr Pharma Inc-Key Employees 24

aTyr Pharma Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Aug 14, 2018: aTyr Pharma announces second quarter 2018 operating results and provides corporate update 26

May 14, 2018: aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring 28

Mar 19, 2018: aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update 29

Nov 14, 2017: aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update 31

Aug 14, 2017: aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline 33

May 11, 2017: aTyr Pharma Announces First Quarter 2017 Operating Results 35

Mar 16, 2017: aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results 37

Corporate Communications 39

Oct 15, 2018: aTyr Pharma announces leadership transition 39

Jul 31, 2018: aTyr pharma appoints Jill Broadfoot as chief financial officer 40

Nov 01, 2017: aTyr Pharma Announces Leadership Transition 41

Apr 10, 2017: aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors 42

Apr 03, 2017: aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors 43

Product News 44

12/21/2017: aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium 44

09/27/2017: aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society 45

05/15/2017: aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar 46

04/24/2017: aTyr Pharma Announces Promising Top-Line Results from Resolaris Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy 47

04/24/2017: aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting 48

Product Approvals 49

Mar 03, 2017: aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris 49

Feb 28, 2017: aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris 50

Jan 18, 2017: FDA Grants Fast Track Designation for aTyr's Resolaris to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris 51

Clinical Trials 52

Nov 27, 2017: aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923) 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

aTyr Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

aTyr Pharma Raises USD76 Million in Series E Financing 11

aTyr Pharma Raises USD 49 Million In Series D Financing 13

Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14

aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15

aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 17

aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 18

aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 20

aTyr Pharma Raises USD86.3 Million in IPO of Shares 21

aTyr Pharma Inc, Key Competitors 23

aTyr Pharma Inc, Key Employees 24

aTyr Pharma Inc, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

aTyr Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.